Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2016

View Archived Issues

Hookipa Biotech initiates first-in-human study of HB-101 vaccine for CMV

Bacillus anthracis capsule conjugate vaccine protects rhesus macaques against inhalational anthrax

Ad-hoc analysis of phase I/II data for lentiviral hemopoietic stem-cell gene therapy

RE-024 shows promise for the treatment of PKAN

New radiological tracer developed for prostate cancer imaging

FDA advisory committee recommends approval of Jardiance in cardiovascular indication

FDA approves Epclusa as pan-genotypic single-tablet regimen for chronic HCV infection

Encouraging results for hNSC transplantation to treat SCI

Celyad reports headline results from CHART-1 phase III study of C-Cure

XOMA starts XOMA-123 phase II study

FDA grants fast track designation to arimoclomol for Niemann-Pick disease type C

Cempra submits solithromycin MAA to EMA

Novel PET radioligand shows promise for measuring brain microglial COX-1

Ablynx to license FOX technology for study of inhaled anti-RSV nanobody

Bio-Path and Thomas Jefferson University sign agreement

AbbVie ends duvelisib collaboration with Infinity Pharmaceuticals

Anthera updates progress of blisibimod and liprotamase programs

Intra-Cellular Therapies begins phase III trial of ITI-007

OmniSeq receives New York CLEP approval for OmniSeq Comprehensive panel

EMA committee recommends granting orphan drug designation to Vicore's C-21 in IPF

European commission grants orphan medicinal product designation to Ultragenyx's burosumab

Two phase III studies of Pfizer's bococizumab meet primary endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...